Hanover, Lower Saxony, 30625, Germany
NCT Number: NCT00961038
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adult patients with COPD, 40 to 75 years of age
- Diagnosis of COPD
- Airway obstruction with a post-bronchodilator Forced Expiratory Volume (FEV1) of >/=30% and </=65% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of </=70%
- Current or ex-smokers with a smoking history of more than 10 pack-years
- Patients must be able to produce acceptable induced sputum samples (as defined in the Study Procedure Manual)
- Normal body weight: Body Mass Index (BMI) between 19 and 35 kg/m2
Exclusion criteria
- Significant respiratory disease other than COPD as bronchial asthma, Cystic fibrosis or clinically evident bronchiectasis
- More than one COPD exacerbation within 12 months and within 8 weeks prior to screening
- total blood eosinophil count >/=600/mm3
- Thoracotomy with pulmonary resection
- Regularly use of daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
- Hypersensitivity to the investigational drug or to other quinolones and/or to inactive constituents of the inhalation powder
- Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution
- Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
- Concomitant use of medication which could interfere with the investigational drug. Before study drug administration a wash out period of more than 5 half lives has to be considered
- Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy with
- fluoroquinolones
- Oral beta-andrenergics, beta blockers
- oral steroids
- Methylxanthines: 24-hour washout of short-acting theophylline and 48-hour washout of long-acting theophylline prior to pre-study examination
- Antihistamines, antileukotrienes prescribed for asthma
- oral cromolyn sodium or oral nedocromil sodium
Treatment and study plan
Ciprofloxacin (PulmoSphere, BAYQ3939)
Drug32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
Placebo
DrugPlacebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
Primary outcomes
-
Vital signs
Time frame: Within 28 days after first treatment
-
Electrocardiogram (ECG)
Time frame: Within 28 days after first treatment
-
Pulmonary function test
Time frame: Within 28 days after first treatment
-
Pulse-oximetry
Time frame: Within 12 days after first treatment
Secondary outcomes
-
Ciprofloxacin concentrations in blood
Time frame: Within 14 days after first treatment
-
Ciprofloxacin concentrations in urine
Time frame: Within 14 days after first treatment
-
Ciprofloxacin concentrations in sputum
Time frame: Within 14 days after first treatment
-
Ciprofloxacin concentrations in mouth fluid
Time frame: Within 7 days after first treatment
Sponsors and collaborators
Lead sponsor
Bayer
Industry
Collaborators
- Novartis Pharmaceuticals
Registry information
Official study title
Randomized, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLD II - III), Following Inhalation of Ciprofloxacin PulmoSphere® Inhalation Powder
Important dates
- Study start
- 2009
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Aug 18, 2009
- Registry last updated
- Apr 1, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
NCT03189589
Chronic Disease, Disease Attributes
Cambridge, United Kingdom
View Trial DetailsA Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection
NCT00711126
Chronic Disease, Disease Attributes
London, United Kingdom
View Trial DetailsAdvair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
NCT00115492
Chronic Disease, Disease Attributes
Jasper, Alabama, United States
View Trial DetailsADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
NCT00144911
Chronic Disease, Disease Attributes
Birmingham, Alabama, United States
View Trial Details